Characterization of mixtures of recombinant human cytochrome P450s as a screening model for metabolic stability in drug discovery

Xenobiotica

Volumn 32, Issue 9, 2002, Pages 749-759

  Hagen, N ^a   Olsen, A K ^a   Andersen, J V ^a   TjOrnelund J ^a   Hansen, S H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; CORTICOSTERONE; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DEXTRORPHAN; OXIDOREDUCTASE; TESTOSTERONE DERIVATIVE; WARFARIN;

ARTICLE; DRUG METABOLISM; DRUG RESEARCH; DRUG STABILITY; ENZYME ACTIVITY; ENZYME KINETICS; ESCHERICHIA COLI; LIVER MICROSOME; SCREENING;

ANTIOXIDANTS; ARYL HYDROCARBON HYDROXYLASES; ASCORBIC ACID; CATALYSIS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ESCHERICHIA COLI; FREE RADICAL SCAVENGERS; HUMANS; KINETICS; MICROSOMES, LIVER; OXIDOREDUCTASES, O-DEMETHYLATING; RECOMBINANT PROTEINS; STEROID HYDROXYLASES; TIME FACTORS;

ANIMALIA; ESCHERICHIA COLI;

EID: 0036746856     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250210147124     Document Type: Article

References (40)

1. Bajpai, M. and Adkison, K. K., 2000, High-throughput screening for lead optimization: a rational approach. Current Opinions in Drug Discovery and Development, 3, 63-71.
2. Crespi, C. L. and Miller, V. P., 1997, The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics, 7, 203-210.
3. Crespi, C. L. and Miller, V. P., 1999, The use of heterologously expressed drug metabolizing enzymes - state of the art and prospects for the future. Pharmacology and Therapeutics, 84, 121-131.
4. Crespi, C. L. and Penman, B. W., 1997, Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Advances in Pharmacology, 43, 171-188.
5. Dai, D., Tang, J., Rose, R., Hodgson, E., Bienstock, R. J., Mohrenweisser, H. W. and Goldstein, J. A., 2001, Identification of variants of CYP3A4 and characterization of their abilities to metabolise testosterone and chlorpyrifos. Journal of Pharmacology and Experimental Therapeutics, 299, 825-831.
6. Eddershaw, P. J. and Dickins, M., 1999, Advances in in-vitro drug metabolism screening. Pharmaceutical Science and Technology Today, 2, 13-19.
7. Eiselt, R., Domanski, T. L., Zibat, A., Mueller, R., Presecan-Siedel, E., Hustert, E., Zanger, U. M., Brockmoller, J., Klenk, H.P., Meyer, U. A., Khan, K. K., He, Y.A., Halpert, J. R. and Wojnowski, L., 2001, Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics, 11, 447-458.
8. Guengerich, F. P., 1995, Human cytochrome P450 enzymes. In P. R. Ortiz de Montellano (ed.), Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd edn (New York: Plenum), pp. 473-535.
9. Gut, J., Catin, T., Dayer, P., Kronbach, T., Zanger, U. and Meyer, U. A., 1986, Debrisoquine/ sparteine-type polymorphism of drug oxidation. Journal of Biological Chemistry, 261, 11734-11743.
10. Houston, J. B. and Kenworthy, K. E., 2000, In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metabolism and Disposition, 28, 246-254.
11. Inoue, K., Yamazaki, H., Imiya, K., Akasaka, S., Guengerich, F. P. and Shimada, T., 1997, Relationship between CYP2C9 and CYP2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics, 7, 103-113.
12. Jones, D. R., Gorski, J. C., Hamman, M. A. and Hall, S. D., 1996, Quantification of dextromethorphan and metabolites: a dual phenotyplc marker for cytochrome P450 3A4/5 and 2D6 activity. Journal of Chromatography B, 678, 105-111.
13. Jung, F., Richardson, T. H., Raucy, J. L. and Johnson, E. F., 1997, Diazepam metabolism by cDNA-expressed human 2C P450s. Drug Metabolism and Disposition, 25, 133-139.
14. Kimura, M., Ieiri, I., Mamiya, K., Urae, A. and Higuchi, S., 1998, Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Therapeutic Drug Monitoring, 20, 243-247.
15. Kohler, D., Härtter, S., Fuchs, K., Sieghart, W. and Hiemke, C., 1997, CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics, 7, 453-461.
16. Korzekwa, K. R., Krishnamachary, N., Shou, M., Ogai, A., Parise, R. A., Rettie, A. E., Gonzalez, F. J. and Tracy, T. S., 1998, Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry, 37, 4137-4147.
17. Lang, D. and Böcker, R., 1995, Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P4502C9 activity. Journal of Chromatography B, 672, 305-309.
18. Lewis, D. F. V., 1998, The CYP2 family: models, mutants and interactions. Xenobiotica, 28, 617-661.
19. Li, D. N., Pritchard, M. P., Hanlon, S. P., Burchell, B., Wolf, C. R. and Friedberg, T., 1999, Competition between cytochrome P450 isozymes for NADPH-cytochrome P-450 oxidoreductase affects drug metabolism. Journal of Pharmacology and Experimental Therapeutics, 289, 661-667.
20. Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
21. McGinnity, D. F., Griffin, S. J., Moody, G. C., Voice, M., Hanlon, S., Friedberg, T. and Riley, R. J., 1999, Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli. Drug Metabolism and Disposition, 27, 1017-1023.
22. McGinnity, D. F., Parker, A. J., Soars, M. and Riley, R. J., 2000, Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metabolism and Disposition, 28, 1327-1334.
23. Moody, G. C., Griffin, S. J., Mather, A. N., McGinnity, D. F. and Riley, R. J., 1999, Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica, 29, 53-75.
24. Omura, T. and Sato, R., 1964, The carbon monoxide-binding pigment of liver microsomes. Journal of Biological Chemistry, 239, 2370-2378.
25. Parkinson, A., 1996, Biotransformation of xenobiotics. In C. D. Klaassen (ed.), Casarett & Doull's Toxicology: The Basic Science of Poisons, 5th edn (New York: McGraw-Hill), pp. 113-186.
26. Pelkonen, O., Mäenp, J., Taavitsainen, P., Rautio, A. and Raunio, H., 1998, Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica, 28, 1203-1253.
27. Pritchard, M. P., Glancey, M. J., Blake, J. A. R., Gilham, D. E., Burchell, B., Wolf, C. R. and Friedberg, T., 1998, Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli. Pharmacogenetics, 8, 33-42.
28. Pritchard, M. P., Ossetian, R., Li, D. N., Henderson, C. J., Burchell, B., Wolf, C. R. and Friedberg, T., 1997, A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. Archives of Biochemistry and Biophysics, 345, 342-354.
29. Reinerink, E. J., Doorn, L., Jansen, E. H. and Van Iersel, A. A., 1991, Measurement of enzyme activities of cytochrome P-450 isoenzymes by high-performance liquid chromatographic analysis of products. Journal of Chromatography, 553, 233-241.
30. Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J. and Trager, W. F., 1992, Hydroxylation of warfarin by human cDNA-expressed cytochrome P450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chemical Research in Toxicology, 5, 54-59.
31. Roberts, S. A., 2001, High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica, 31, 557-589.
32. Shimida, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P., 1994, Interindividual variation in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
33. Van Der Hoeven, T., 1984, Assay of hepatic microsomal testosterone hydroxylases by high performance liquid chromatography. Analytical Biochemistry, 138, 57-65.
34. Venkatakrishnan, K., Von Moltke, L. L., Court, M. H., Harmatz, J. S., Crespi, C. L. and Greenblatt, D. J., 2000, Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metabolism and Disposition, 28, 1493-1504.
35. Vermilion, J. L. and Coon, M. J., 1978, Purified liver microsomal NADPH-cytochrome P450 reductase. Journal of Biological Chemistry, 253, 2694-2704.
36. 5 on CYP3A4 activity and stability in vivo. Archives of Biochemistry and Biophysics, 366, 116-124.
37. Von Moltke, L. L., Greenblatt, D. J., Grassi, J. M., Granda, B. W., Venkatakrishnan, K., Schmider, J., Harmatz, J. S. and Shader, R. I., 1998, Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. Journal of Pharmacy and Pharmacology, 50, 997-1004.
38. White, R. E., 1998, Short- and long-term projections about the use of drug metabolism in drug discovery and development. Drug Metabolism and Disposition, 26, 1213-1216.
39. Yamazaki, H. and Shimada, T., 1997, Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Archives of Biochemistry and Biophysics, 346, 161-169.
40. Yamazaki, H., Inoue, K. and Shimada, T., 1998, Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica, 28, 103-115.